Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: Preclinical and clinical studies

Joint Bone Spine

Volumn 69, Issue 1, 2002, Pages 12-18

  Feldmann, Marc ^a   Maini, Ravinder N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Cytokines; Infliximab; Rheumatoid arthritis; Therapy

Indexed keywords

CYTOKINE; EPITOPE; ETANERCEPT; HLA ANTIGEN CLASS 2; INFLIXIMAB; LENERCEPT; MACROGOL; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; EUROPE; HLA SYSTEM; HUMAN; IMMUNOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; UNITED STATES;

EID: 0036160864     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(01)00335-9     Document Type: Review

References (55)

1. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
2. Role of cytokines in rheumatoid arthritis
3. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition
4. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1
5. Cytokines in chronic inflammatory arthritis. II granulocytemacrophage colony-stimulating factor in rheumatoid synovial effusions
6. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies
7. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: Relevance for autoimmunity
8. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity
9. Rheumatoid arthritis: A disease of T-lymphocyte/macrophage immunoregulation
10. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis
11. The structure of eight distinct cloned human leukocyte interferon cDNAs
12. Structure and expression of a cloned cDNA for human interleukin-2
13. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA
14. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-1α
15. Anti-TNFα therapy or rheumatoid arthritis: What have we learned?
16. Immunoregulatory role of interleukin 10 in rheumatoid arthritis
17. Elevated interleukin-10 levels in patients with rheumatoid arthritis
18. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium
19. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: Implications for TGF-β-driven synovial inflammation and hyperplasia
20. Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever
21. Cytokine production in culture by cells isolated from the synovial membrane
22. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
23. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha
24. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocytemacrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNF-α
25. Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis
26. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis
27. Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis
28. Successful transfer of collagen-induced arthritis to SCID mice
29. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
30. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
31. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
32. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
33. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
34. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
35. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
36. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
37. Randomised phase III trial of infliximab (chimeric anti-TNFa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate
38. Infliximab and methotrexate in the treatment of rheumatoid arthritis
39. 102 Week clinical and radiological results from the ATTRACT trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active rheumatoid arthritis despite methotrexate
40. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis
41. Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a European phase II trial
42. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG1, Ro 45-2081) in patients with rheumatoid arthritis: Results from open label extension of a double blind single-dose phase I study
43. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein
44. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
45. Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7
46. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): Novel high affinity TNF receptor designed for chronic inflammatory diseases
47. Efficacy of a novel pgylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis
48. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α
49. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
50. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
51. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
52. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis
53. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis
54. Elevated vascular endothelial growth factor in early rheumatoid arthritis abstract